PharmaBioSource Realty represented SHL Medical (www.shl-medical.com) on the lease of its new U.S. medical device injection molding manufacturing facility in Charleston, SC. The facility totals 270,000 SF of space and SHL is planning a $90M investment over the next 2 years. Once operational in 2024, SHL will employ 165 staff to support its growing autoinjector device manufacturing demands.
SunCap – SHL Medical Palmetto Trade Center Announcement
PharmaBioSource Realty has sold Teligent’s injectable fill / finish and topical liquids and creams manufacturing and packaging facility to Leiters for $27M.
Sever Pharma Solutions (SPS) acquired the assets of Foster Delivery Services (FDS) in Putnam, Connecticut. The acquisition significantly expands SPS’s ability to leverage its expertise in the development of high-potent pharmaceutical products.
PharmaBioSource and PharmaBioSource Realty represented Micelle Biopharma on the sale of its soft gel manufacturing and laboratory assets and also facilitated the lease of its 73,550 SF development and manufacturing facility in Riviera Beach, Florida to Strides USA.
Bill Wiederseim, President & CEO of PharmaBioSource, Inc., meets with That’s Nice to discuss the importance of setting expectations for facility and M&A transactions in the CDMO sector to ensure a smooth and successful transaction process.
PharmaBioSource Realty provided exclusive marketing and real estate services to sell Shire’s biologics drug substance manufacturing site located in Milford, MA. The Milford site was acquired by Rentschler Biopharma, which will utilize the site as its U.S. contract manufacturing and development headquarters. The transaction included a supply agreement for Rentschler to manufacture Obizur through Shire’s proprietary roller bottle process. In addition to the acquisition of the 93,000 SF facility, Rentschler will retain approximately 100 staff employed at the site.
PharmaBioSource exclusively represented Luitpold’s Osteohealth Division on the sale of GEM 21S® fully synthetic growth-factor enhanced matrix to treat periodontally related defects. GEM 21S® utilizes innovative tissue engineering principles combining a highly purified bioactive protein, rhPDGF-BB, with an osteoconductive matrix, B-TCP. GEM 21S® is a fully synthetic, sterile injectable grafting system designed to stimulate wound healing and bone regeneration. PharmaBioSource managed the process to divest the GEM 21S® asset to potential buyers and investors, including target identification and marketing, data room development, due diligence oversight, negotiations and closing support. The GEM 21S® asset was acquired by Lynch Biologics in September 2018.